不同基础肝病病因的肝硬化患者特征差异与生存结局
该研究分析了2005年1月至2022年1月在斯坦福大学医学中心就诊的8726例连续成人肝硬化患者,按病因分组比较生存结局。结果显示隐源性肝硬化患者5年、10年和15年累积生存率最低(57.5%、34.3%和21.4%),HBV患者最高(86.0%、70.1%和65.1%)。多变量Cox回归中隐源性肝硬化(vs. HBV)的全因死亡风险最高(aHR:2.24,95%CI 1.67-3.00)。2010年后全因死亡风险降低33%(p=0.0011)。
要点
- 隐源性肝硬化5年、10年、15年累积生存率分别为57.5%、34.3%、21.4%,为各病因中最低。
- HBV肝硬化5年、10年、15年累积生存率分别为86.0%、70.1%、65.1%,为各病因中最高。
- 隐源性肝硬化(vs. HBV)全因死亡aHR为2.24(95%CI 1.67-3.00),风险最高。
核心结论
- 肝硬化患者生存结局因病因不同而异,且随时间变化,未来实践指南和建模研究应予以考虑。
研究设计与样本
- 研究分析了2005年1月至2022年1月在斯坦福大学医学中心就诊的8726例连续成人肝硬化患者。
主要发现
- 8726例患者病因构成:HCV 28.1%、HBV 4.8%、酒精相关(ALD)33.3%、代谢相关脂肪性肝病(MASLD)9.5%、自身免疫性9.6%、隐源性8.2%、其他病因6.5%。
- 隐源性肝硬化患者总体5年、10年和15年累积生存率最低(57.5%、34.3%和21.4%),肝脏相关和非肝脏相关死亡亦然,其次为ALD、MASLD、HCV和自身免疫性,HBV患者生存率最高(86.0%、70.1%和65.1%)。
- 多变量Cox回归中,隐源性肝硬化(vs. HBV)与全因死亡风险最高相关(aHR:2.24,95%CI 1.67-3.00),其次为MASLD和ALD(均p < 0.001)。
- 2010年后时间段与全因死亡风险降低33%相关(p = 0.0011);在2010年后时期,MASLD(vs. HBV)与全因死亡风险最高相关(aHR:1.92,95%CI 1.32-2.80,p < 0.001),其次为隐源性和ALD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Updated data on the survival of patients with cirrhosis are limited, especially for subgroups by specific liver disease aetiology. To inform practice, future modelling studies, and public health planning, our study aimed to provide updated and granular data on survival outcomes of patients with cirrhosis stratified by liver disease aetiology. We also assessed their changes over time. METHODS: We analysed 8726 consecutive adult patients with cirrhosis who presented at Stanford university medical center during 1/2005-1/2022. RESULTS: 8726 Patients had the following etiologies: hepatitis C virus (HCV) (28.1%), hepatitis B virus (HBV) (4.8%), alcohol-associated (ALD, 33.3%), metabolic-associated steatotic liver disease (MASLD) (9.5%), autoimmune (9.6%), cryptogenic (8.2%) and other etiologies (6.5%). Patients with cryptogenic cirrhosis had the lowest overall 5-, 10-, and 15-year cumulative survival (57.5%, 34.3% and 21.4%), as well as for liver and nonliver-related death, followed by ALD, MASLD, HCV, and autoimmune, while HBV patients had the best survival (86.0%, 70.1% and 65.1%), respectively. On multivariable Cox regression, cryptogenic cirrhosis (vs. HBV) was associated with the highest risk of all-cause death (aHR: 2.24, 95% CI 1.67-3.00), followed by MASLD and ALD (all p < 0.001). Post-2010 time was associated with a 33% lower risk of all-cause death (p = 0.0011); While in the post-2010 period, MASLD (vs. HBV) was associated with the highest risk of all-cause death (aHR: 1.92, 95% CI 1.32-2.80, p < 0.001) followed by cryptogenic and ALD. CONCLUSIONS: Survival outcomes in patients with cirrhosis varied by aetiology and have changed over time, which should be taken into account for future practice guidelines and modelling studies.
引用
- Shi Y, Chien N, Fong A, et al. Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology. Aliment Pharmacol Ther. 2025. PMID: 40013475. doi:10.1111/apt.70059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。